Reply to H. Shojima et al
- PMID: 33979207
- PMCID: PMC8331061
- DOI: 10.1200/JCO.21.00684
Reply to H. Shojima et al
Conflict of interest statement
Comment on
-
Phase III Randomized Controlled Trial of eRAPID: eHealth Intervention During Chemotherapy.J Clin Oncol. 2021 Mar 1;39(7):734-747. doi: 10.1200/JCO.20.02015. Epub 2021 Jan 8. J Clin Oncol. 2021. PMID: 33417506 Clinical Trial.
-
How Can We Evaluate the Electronic Patient-Reported Outcome Appropriately?J Clin Oncol. 2021 Aug 10;39(23):2632-2633. doi: 10.1200/JCO.21.00482. Epub 2021 May 12. J Clin Oncol. 2021. PMID: 33979201 No abstract available.
References
-
- Shojima H, Shimomura A, Kadowaki M, et al. How can we evaluate the electronic patient-reported outcome appropriately? J Clin Oncol 392632–26332021 - PubMed
-
- Absolom K, Warrington L, Hudson E, et al. Phase III randomized controlled trial of eRAPID: eHealth intervention during chemotherapy J Clin Oncol 39734–7472021 - PubMed
-
- Holch P, Warrington L, Potrata B, et al. Asking the right questions to get the right answers: Using cognitive interviews to review the acceptability, comprehension and clinical meaningfulness of patient self-report adverse event items in oncology patients Acta Oncol 551220–12262016 - PubMed
-
- Absolom K, Gibson A, Velikova G.Engaging patients and clinicians in online reporting of adverse effects during chemotherapy for cancer: The eRAPID system (electronic patient self-Reporting of Adverse-events: Patient Information and aDvice) Med Care 57S59–S652019 - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
